Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1980 1
1997 2
2001 1
2002 2
2003 2
2006 2
2007 2
2008 24
2009 50
2010 90
2011 117
2012 167
2013 216
2014 253
2015 321
2016 337
2017 393
2018 444
2019 530
2020 647
2021 762
2022 666
2023 672
2024 264

Text availability

Article attribute

Article type

Publication date

Search Results

5,299 results

Results by year

Filters applied: . Clear all
Page 1
Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L, Duan JJ, Bian XW, Yu SC. Yin L, et al. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5. Breast Cancer Res. 2020. PMID: 32517735 Free PMC article. Review.
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include hi …
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express es …
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM. Keenan TE, et al. J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. J Natl Compr Canc Netw. 2020. PMID: 32259782 Review.
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast cancer (TNBC), which ha …
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent eff …
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP. Leon-Ferre RA, et al. BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. BMJ. 2023. PMID: 37253507 Review.
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. ...Furthermore, advances in drug development have led to the approval of antibody-drug conjugates that a …
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest …
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R. Kumar P, et al. Arch Gynecol Obstet. 2016 Feb;293(2):247-69. doi: 10.1007/s00404-015-3859-y. Epub 2015 Sep 4. Arch Gynecol Obstet. 2016. PMID: 26341644 Review.
PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors comprising various breast cancers simply defined by the absence of estrogen receptor, progesterone receptor and overexpression of human epidermal growth factor rece …
PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors comprising various breast …
Triple-negative breast cancer: recent treatment advances.
Bergin ART, Loi S. Bergin ART, et al. F1000Res. 2019 Aug 2;8:F1000 Faculty Rev-1342. doi: 10.12688/f1000research.18888.1. eCollection 2019. F1000Res. 2019. PMID: 31448088 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. ...Recently published advances in the trea …
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affec …
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Garrido-Castro AC, Lin NU, Polyak K. Garrido-Castro AC, et al. Cancer Discov. 2019 Feb;9(2):176-198. doi: 10.1158/2159-8290.CD-18-1177. Epub 2019 Jan 24. Cancer Discov. 2019. PMID: 30679171 Free PMC article. Review.
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. ...SIGNIFICANCE: TNBC is characterized by higher rates of relapse, greater metastatic potential, and shorter overall survival compare …
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. …
Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression.
Arroyo-Crespo JJ, Armiñán A, Charbonnier D, Deladriere C, Palomino-Schätzlein M, Lamas-Domingo R, Forteza J, Pineda-Lucena A, Vicent MJ. Arroyo-Crespo JJ, et al. Int J Cancer. 2019 Oct 15;145(8):2267-2281. doi: 10.1002/ijc.32270. Epub 2019 Apr 2. Int J Cancer. 2019. PMID: 30860605 Free PMC article.
Triple-negative breast cancer (TNBC), an aggressive, metastatic and recurrent breast cancer (BC) subtype, currently suffers from a lack of adequately described spontaneously metastatic preclinical models that faithfully repr …
Triple-negative breast cancer (TNBC), an aggressive, metastatic and recurrent breast cancer …
Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D. Kwapisz D. Cancer Immunol Immunother. 2021 Mar;70(3):607-617. doi: 10.1007/s00262-020-02736-z. Epub 2020 Oct 5. Cancer Immunol Immunother. 2021. PMID: 33015734 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen (ER) and progesterone (PgR) receptors as well as human epidermal growth factor receptor 2 (HER2) and is associated with poor prognosis. Moreover, the systemic trea …
Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen (ER) and progesterone ( …
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M. Agostinetto E, et al. Expert Opin Investig Drugs. 2022 Jun;31(6):567-591. doi: 10.1080/13543784.2022.2049232. Epub 2022 Mar 9. Expert Opin Investig Drugs. 2022. PMID: 35240902 Review.
INTRODUCTION: Triple negative breast cancer (TNBC) is an area of high unmet medical need in terms of new effective treatment strategies. Although breast cancer is traditionally considered a 'cold' tumor type, TNBC is the most appropriate …
INTRODUCTION: Triple negative breast cancer (TNBC) is an area of high unmet medical need in terms of new effecti …
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai X, Ni J, Beretov J, Graham P, Li Y. Bai X, et al. Cancer Lett. 2021 Jan 28;497:100-111. doi: 10.1016/j.canlet.2020.10.016. Epub 2020 Oct 16. Cancer Lett. 2021. PMID: 33069769 Review.
Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is poorer, with an early tendency to metastasis and a higher recu …
Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other bre …
5,299 results